Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Dec 21, 2022
Date Accepted: Dec 27, 2023
Date Submitted to PubMed: Dec 28, 2023

The final, peer-reviewed published version of this preprint can be found here:

A Deep Learning–Based Approach for Prediction of Vancomycin Treatment Monitoring: Retrospective Study Among Patients With Critical Illness

Kim D, Choi HS, Lee D, Kim M, Kim Y, Han SS, Heo Y, Park JH, Park J

A Deep Learning–Based Approach for Prediction of Vancomycin Treatment Monitoring: Retrospective Study Among Patients With Critical Illness

JMIR Form Res 2024;8:e45202

DOI: 10.2196/45202

PMID: 38152042

PMCID: 10960205

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

A deep learning approach to predicting vancomycin therapeutic drug monitoring in critically ill patients

  • Dohyun Kim; 
  • Hyun-Soo Choi; 
  • DongHoon Lee; 
  • Minkyu Kim; 
  • Yoon Kim; 
  • Seon-Sook Han; 
  • Yeonjeong Heo; 
  • Ju-Hee Park; 
  • Jinkyeong Park

ABSTRACT

Background:

The pharmacokinetic profile of vancomycin is highly variable, especially in critically ill patients. Various deep learning models have been successful so far in the decision-making system that predicts the vancomycin therapeutic drug monitoring (TDM) level in patients in the intensive care unit (ICU).

Objective:

We aimed to establish an ideal model by comparing and integrating methods in the decision-making system that predicts the vancomycin TDM level in ICU patients.

Methods:

We proposed novel deep learning model, the joint multilayer perceptron (JointMLP) for predicting vancomycin TDM level and compared the performance of a population pharmacokinetic (PPK) model, extreme gradient boosting, and TabNet, respectively, with data collected from Dongguk University Ilsan Hospital (DUIH) and Kangwon National University Hospital (KNUH).

Results:

Of the 977 DUIH datasets, 97 were used as the test set while the remaining 879 were used as the training data set. The external validation subject was data from 1,429 KNUH subjects. For the external data set, all models were found to have significantly higher predictive power than PPK. However, in internal datasets, the JointMLP model showed significantly better performance in predicting vancomycin TDM than the PPK model (root mean squared error 8.27 vs. 10.38, P < 0.01). The JointMLP model showed better predictive performance than other models, including the PPK model, in the external dataset. The most influential variables in TDM prediction were the vancomycin volume of distribution, sex, and height in both internal and external datasets. These variables consistently had high SHAP values in both datasets

Conclusions:

JointMLP implementation for clinical use will not only provide optimal vancomycin doses but also provide many improvements in itself as the data are continuously updated, which will result in continued increments in accuracy.


 Citation

Please cite as:

Kim D, Choi HS, Lee D, Kim M, Kim Y, Han SS, Heo Y, Park JH, Park J

A Deep Learning–Based Approach for Prediction of Vancomycin Treatment Monitoring: Retrospective Study Among Patients With Critical Illness

JMIR Form Res 2024;8:e45202

DOI: 10.2196/45202

PMID: 38152042

PMCID: 10960205

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.